Cambridge Angels

In an episode of two halves, we talk to Amy Weatherup about two decades leading i-Teams Cambridge and her personal journey before and since. iTeams bridges the gap between students who are experts in their own sector, and entrepreneurs and innovators who are looking to drive commercialisation and turn their ideas to reality. Amy tells us more including three lessons she’s learnt along the way: • Technology is far earlier than you think it is • It’s going to cost you a lot more money • IP and patents are only part of what you have We then talk about Amy’s own career at the start of the commercial internet, and supporting schools to startups. We cover: • Being a young entrepreneur • Building a company, quickly, and keeping cash flowing • Contracts with some of the largest electronics companies • How securing funding has changed over the last decades • Being open with corporates • Angel investing • Paying it forward Tune in on your chosen podcast platform to subscribe and listen. Apple podcast: https://apple.co/3P9RegV Google podcast: https://bit.ly/CTPgoogle Spotify: https://lnkd.in/enP_4QVr Amazon Music: https://amzn.to/3VHqGGs YouTube: https://lnkd.in/eAg5Wv42 Acast: https://lnkd.in/esg7xgq2 CamTechPod: https://lnkd.in/eB5Aznm6 #CamTechPod, John Bull, Cambridge Science Centre, University of Cambridge, Cambridge Enterprise, Cambridge Enterprise Ventures, Raspberry Pi, Peter Cowley (he/him), Ruizhi Wang, Global Volcano Risk Alliance, Founders at the University of Cambridge, Institute for Manufacturing (IfM), University of Cambridge, Lara Allen, Centre for Global Equality, Alexander Patto, WaterScope, William Oak Diagnostics, Simon Pulman-Jones, Xampla, Tuomas Knowles, Massachusetts Institute of Technology, Tom Collings, Kalium Health, Tanya Hutter, PhD, Intelligent Fingerprinting, Acorn Computers, Symbian, Brother International GmbH, Microsoft, Arm, 3i, Deeptech Labs, Cambridge Angels, Sherry Coutu CBE, Martlet Capital

🚀 Exciting News! 🚀 We're thrilled to announce that first patients have been recruited to VISION - our observational study aimed at transforming the treatment of early triple-negative breast cancer (TNBC)! VISION will not only identify biomarkers of therapy response but also enhance the precision of therapeutic predictions for individual patients using Concr’s cutting-edge FarrSight®-Twin alongside standard diagnostic tests. 🤝 AI-VISION: A synergistic collaboration This multi-disciplinary initiative brings together the expertise of Concr, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Durham University. Funded by Innovate UK, AI-VISION leverages the power of multi-modal data and Concr’s proprietary Bayesian frameworks to uncover innovative treatment pathways for TNBC. 🌟 Why this matters TNBC is an aggressive cancer and an alarming 40% of women die within 5 years of their initial cancer diagnosis. More reliable biomarkers and novel approaches to treatment stratification offer hope to significantly improve survival. This study is also set to contribute to the body of evidence supporting the efficacy and safety of advanced computational methods in enabling precision medicine, ultimately aiming to improve patient outcomes. Read the full press release here: https://lnkd.in/eBgbTEtu And stay tuned for updates as we embark on this journey to transform TNBC care! #TechBio #Oncology #TNBC #BreastCancer #DigitalTwin #ClinicalTrials #AI #PrecisionMedicine #FromCosmologyToOncology